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Abstract
Epithelial Protein Lost in Neoplasm a is a novel cytoskeleton-associated tumor suppressor whose expression inver-
sely correlates with cell growth, motility, invasion and cancer mortality. Here we show that Eplin-a transcription is
regulated by actin-MAL-SRF signalling. Upon signal induction, the coactivator MAL/MRTF is released from a repres-
sive complex with monomeric actin, binds the transcription factor SRF and activates target gene expression. In a
transcriptome analysis with a combination of actin binding drugs which specifically and differentially interfere with
the actin-MAL complex (Descot et al., 2009), we identified Eplin to be primarily controlled by monomeric actin.
Further analysis revealed that induction of the Eplin-a mRNA and its promoter was sensitive to drugs and mutant
actins which stabilise the repressive actin-MAL complex. In contrast, the Eplin-b isoform remained unaffected.
Knockdown of MRTFs or dominant negative MAL which inhibits SRF-mediated transcription impaired Eplin-a
expression. Conversely, constitutively active mutant actins and MAL induced Eplin-a. MAL and SRF were bound to
a consensus SRF binding site of the Eplin-a promoter; the recruitment of MAL to this region was enhanced sever-
alfold upon induction. The tumor suppressor Eplin-a is thus a novel cytoskeletal target gene transcriptionally regu-
lated by the actin-MAL-SRF pathway, which supports a role in cancer biology.
Findings
Epithelial Protein Lost in Neoplasm (referred to as Eplin)
is a novel tumor suppressor affecting cell growth, cytos-
keletal organisation and motility [1,2]. Eplin crosslinks,
bundles and stabilises F-actin filaments and stress fibers,
which correlates with its ability to suppress anchorage-
independent growth in transformed cells [3-5]. In epithe-
lial cells, Eplin is required for formation of the F-actin
adhesion belt by binding to the E-cadherin-catenin com-
plex through a-catenin [6].
Eplin is encoded by Lima1 (LIM domain and actin
binding-1) and expressed in two isoforms from distinct
promoters: a longer Eplin-b (confusingly also called
Eplin 1 or variant a) and a shorter Eplin-a (sometimes
called Eplin 2 or variant b) [2,7]. Eplin-a mRNA is
detected in various tissues and cell lines, but strikingly
absent or downregulated in cancer cells [2]. In human
breast cancer, its expression inversely correlates with
poor prognosis, invasiveness and mortality [1]. Here we
show that expression of the Lima1 gene is considerably
affected by G-actin signalling (Fig. 1A).
Monomeric G-actin controls the activity of the tran-
scription factor Serum Response Factor (SRF) by form-
ing a repressive complex with its coactivator MAL/
MRTF [8-10]. Upon Rho-family induced signal induc-
tion, MAL is released from actin, binds SRF and acti-
vates target gene expression [8,11-15]. Actin binding
drugs differentially affect this subset of SRF target genes:
treatment with cytochalasin D activates transcription by
releasing MAL from G-actin, whilst latrunculin B stabi-
lises the G-actin:MAL complex and inhibits gene
expression [15-18].
Using this effect, we recently searched for G-actin
regulated genes in NIH 3T3 cells by microarray expres-
sion analysis (GEO dataset GSE17105) [19]. Since both
drugs depolymerised F-actin, genes depending on an
intact cytoskeleton rather than on the G-actin switch
did not score as differentially expressed. Strikingly, we
found all four independent probe sets of the Lima1
gene (old Affymetrix annotation D15Ertd366e) to be
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any medium, provided the original work is properly cited.differentially regulated (Fig. 1A). They were induced by
cytochalasin between 3.5 and 5.2 fold, and simultanously
repressed by latrunculin to 40-50%; statistical signifi-
cance for differential regulation was high.
To validate our microarray result and to determine
the regulated Eplin isoform, quantitative RT-PCR was
performed. Endogenous Eplin-a mRNA was significantly
upregulated by cytochalasin treatment, and this induc-
tion was repressed by latrunculin, whilst Eplin-b mRNA
remained unaffected (Fig. 1B). This suggests that tran-
scription from the Eplin-a promoter, but not from the
Eplin-b promoter, is regulated by G-actin. In addition,
Eplin-a was induced by serum independently from pro-
tein translation, consistent with its previous characteri-
sation as an immediate-early serum responsive gene
(Fig. 1C and data not shown) [7]. Importantly, the
serum induction of Eplin-a was significantly inhibited
by latrunculin pretreatment (Fig. 1C).
In parallel to Rho-actin signalling, serum stimulation
also activates the MAPK pathway and facilitates SRF-
dependent transcription through ternary complex factors
(TCFs). To determine a potential role of MAPK signal-
ling in Eplin-a transcription, cells were pretreated with
the MEK inhibitor UO126. A slight but significant reduc-
tion of serum-induced Eplin-a mRNA was observed,
whereas cytochalasin induction was essentially unaffected
(Fig. 1D).
Next we investigated whether the Eplin-a promoter
mediates regulation of heterologous luciferase reporter
constructs, initially continuing with our NIH 3T3 model
system. A 1934 bp fragment of the murine Eplin-a pro-
moter, including the transcription start site, was activated
by serum and cytochalasin, and its induction was reduced
significantly by latrunculin pretreatment (Fig. 2A). To
further identify a potential G-actin response element,
several promoter deletions were analysed (Fig. 2B). In
contrast to Eplin-b,a l lE p l i n - a constructs were regulata-
ble by serum, cytochalasin and latrunculin (Fig. 2C). This
included the -915 construct, which lacks a possible SRF
binding site around nucleotide -1050. The results suggest
that a proximal promoter element is sufficient for Eplin-
a regulation through actin. Consistent with this, the
murine Eplin-a promoter harbours a consensus SRF
binding site (CArG box) at -124 (gtCCTTATAAGGc-
tatcctg), which is conserved in the human promoter; the
Eplin-b promoter lacks any obvious CArG boxes [7].
Since Eplin-a was described as a protein enriched in
epithelial cells, where it plays a critical role in adherens
junction formation, we also determined the regulation in
mouse mammary epithelial cells. Despite a generally lower
level of induction by actin drugs in this cell type [20], the
reporter was upregulated by both cytochalasin and jaspla-
kinolide (an F-actin stabilising drug and inducer of actin-
MAL signalling; [8]) and inhibited by latrunculin. This
Figure 1 Eplin-a expression is regulated by signalling through
G-actin. (A) Four independent Affymetrix probe sets of the Lima1
gene encoding Eplin were differentially regulated by actin binding
drugs. G-actin regulated genes were induced by treatment with
cytochalasin D (CD,2μM, 90 min) and repressed by latrunculin B (LB,
5 μM). Results shown are from transcriptome analysis of NIH 3T3
fibroblasts as previously described [19].
The q-value is the lowest false discovery rate at which the differentially
expressed probe set is called significant. (B) Validation of differential
regulation of Eplin-a, but not of Eplin-b, by actin binding drugs. NIH
3T3 cells were treated with cytochalasin D (2 μM) for 120 min, or with
cytochalasin following 30 min pretreatment with latrunculin B (5 μM).
Controls were left untreated (un.). The total mRNA was isolated and
subjected to quantitative RT-PCR as described [19]. Shown is the
average induction of Eplin mRNA after normalisation to hprt. Error bars
indicate SEM (n = 3) for Eplin-a, and half range for Eplin-b. (C, D) Effect
of pretreatment with latrunculin B (C) or UO126 (10 μM, 30 min) on
the average induction of Eplin-a mRNA by serum (FCS,
15%, 90 min). Error bars indicate SEM of at least three independent
experiments. The used primers were (positions of mRNA): Eplin-a,
® (
1203GCTGTTTCCGATGCTCCTAC
1223), ¬ (
1382CTCATTGTCGCTCTTGCT
TG
1362); Eplin-b, ® (
183CAAGAACAAGTCATCCGCAAT
204),
¬ (
418AGGAGGGTAGTCCGCTGTGT
398). Asterisk, significant activation;
double asterisk, significant repression (p < 0.01, unpaired student’s
t-test).
Leitner et al. Molecular Cancer 2010, 9:60
http://www.molecular-cancer.com/content/9/1/60
Page 2 of 6suggests that the mode of Eplin-a regulation is not funda-
mentally different in epithelial cells.
A nonpolymerisable point mutant actin, R62D, is not
incorporated into F-actin filaments, but increases the total
cellular G-actin level, binds to MAL, and consequently
inhibits SRF activation [8,17]. In contrast, G15S enhances
F-actin formation and constitutively activates MAL and
SRF independently from upstream signals [16]. Thus we
ectopically expressed these actins together with the Eplin-
a reporter to demonstrate its direct regulation by G-actin.
Actin R62D as well as actin wildtype significantly inhibited
the Eplin-a reporter induction by cytochalasin (Fig. 3A);
a reduction was even observable following serum-stimula-
tion (Additional file 1, Fig. S1A). Conversely, G15S acti-
vated Eplin-a in the absence of stimuli. Despite the low
transfection rate of around 20%, similar effects were also
observed on the total endogenous Eplin-a mRNA (Addi-
tional file 1, Fig. S1B). Moreover, it was previously shown
that Eplin-a is activated by Rho family GTPases [7], which
are critical inducers of G-actin:MAL dissociation [8]. This
shows that the Eplin-a promoter resembles the regulation
of MAL-dependent SRF target genes.
To directly test the effect of MAL on Eplin-a, we transi-
ently infected cells with constitutively active MAL ΔN,
which lacks the N-terminal actin-binding RPEL-motifs
[8,18]. In addition, MAL(met) and MAL full length were
analysed, which contain 2 or all 3 regulatory RPEL
motifs, respectively. MAL ΔN and MAL(met) signifi-
cantly induced endogenous Eplin-a mRNA expression
(Fig. 3B). MAL full length exhibited the weakest activity,
consistent with its tightest regulation through actin.
This result demonstrated that MAL is sufficient to
induce Eplin-a and identifies it as a MAL target gene.
Conversely, we determined whether MAL and MRTF-B
are required for serum induction. Dominant negative
constructs which either lack the SRF-binding basic region
(ΔNΔB) or the C-terminal transactivation domain
(ΔNΔC )w e r eu s e d .I na d d i t i o n ,t r a n s i e n tr e t r o v i r a l
knockdown of both MAL and MRTF-B by shRNA was
performed [19]. Interestingly, only MAL ΔNΔCs i g n i f i -
cantly inhibited serum induction of Eplin-a,w h e r e a s
ΔNΔB or a partial MRTF knockdown had little effect in
NIH 3T3 cells (Fig. 3C). Consistent with this, MAL
ΔNΔC is thought to block MAL/SRF function by forming
a transcriptionally inactive SRF complex on target pro-
moters. This complex, through interaction of the MAL
basic region with the SRF B-box, does not permit simul-
tanous formation of ternary complexes between SRF and
the MAPK-regulated cofactors of the TCF-family [13,21].
In contrast, MAL ΔNΔB retains endogenous MAL via
the leucine-zipper in an inactive, cytoplasmic state, but
does not compete with TCF binding to the common SRF
surface [13,22]. This suggests that Eplin-a can be regu-
lated by both actin-MAL and MAPK-TCF signals. In line
Figure 2 The proximal promoter of Eplin-a is regulated through
actin. (A) The extended Eplin-a promoter confers regulation to a
luciferase reporter gene. A genomic fragment covering nucleotides
-1802 to +132 relative to the putative transcription start site of Eplin-a
was cloned from murine liver tissue into the luciferase reporter
plasmid pGL3. Following the indicated pretreatment with latrunculin B
(5 μM, 30 min) and 7 hours of stimulation with serum (15%) or
cytochalasin D (2 μM), transiently transfected NIH3T3 cells were lysed
and the luciferase activity was determined as described [17]. (B)
Schematic diagram of the genomic structure of the Eplin gene, and
the promoter reporter constructs used. The Eplin-b reporter ranges
from -1249 to +71, and the truncated Eplin-a fragments range from
the indicated nucleotide to +284, relative to the transcription start site.
(C) Analysis of the Eplin promoter reporter constructs by transient
luciferase assays in NIH 3T3 fibroblasts. Shown is the mean relative
luciferase activity, normalised to Renilla luciferase. Error bars, SEM (n =
3). (D) The proximal Eplin-a promoter is differentially regulated by
actin binding drugs in mouse mammary epithelial EpH4 cells. Cells
were transiently transfected with the Eplin-a (-915) promoter reporter
construct, treated with cytochalasin, latrunculin, or jasplakinolide (0.5
μM, 7 h), and analysed as described [20]. Shown is the mean relative
luciferase activity, with Error bars indicating half range. Asterisk,
significant activation; double asterisk, significant repression (p < 0.05,
unpaired student’st - t e s t ) .
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fibroblasts is inhibited strongly by latrunculin and slightly
by UO126 (Fig. 1C, D), and the Eplin-a promoter is
known to contain TCF-binding sites adjacent to the SRF-
binding CArG-box [7].
In order to determine the regulation of Eplin-a by
MAL in epithelial cells, we stably infected mouse mam-
mary epithelial cells with constitutively active MAL ΔN,
MAL(met) and the MAL/MRTF-B knockdown construct.
As observed in fibroblasts before, MAL ΔNa n dM A L
(met) significantly induced endogenous Eplin-a mRNA
expression in epithelial cells. (Fig. 3D). In addition, stable
double knockdown of MRTFs decreased the endogenous
Eplin-a mRNA level, showing that MRTFs are sufficient
and required for Eplin-a expression in epithelial cells.
Finally, the recruitment of MAL and SRF to the Eplin-a
promoter was analysed by chromatin immunoprecipita-
tions from cells treated with and without cytochalasin.
The known MAL-regulated srf gene and the gapdh gene
were used as controls. Eplin-a was bound by SRF and
inducibly recruited MAL upon cytochalasin stimulation,
similar to the srf positive control (Fig. 4A). In contrast,
neither the control antibody nor the gapdh gene resulted
in a positive ChIP. Quantitive PCR following ChIP
revealed that MAL recruitment to both Eplin-a and
srf promoters is induced more than 10-fold, whilst SRF
recruitment is only slightly enhanced (Fig. 4B). Moreover,
SRF- and inducible MAL-recruitment were also detected
after serum stimulation, comparable for srf and Eplin-a
genes (Fig. 1C). Together, these results strongly suggest
that the Eplin-a promoter is inducibly bound and regu-
lated by MAL through its interaction with SRF.
Based on this study, we conclude that expression of the
Eplin-a gene is transcriptionally regulated by actin-MAL
signalling. The endogenous mRNA and the promoter of
Eplin-a is induced by serum, actin binding drugs, Rho
family members [7], constitutively active actin mutants,
and MAL, and is negatively controlled by drugs which sta-
bilise the repressive actin-MAL complex, by non-poly-
merisable actin mutants, and by dominant negative MAL
or MRTF knockdown. In addition, the Eplin-a gene
recruits SRF and, upon induction, MAL to a region con-
taining a conserved CArG consensus site. The tumor sup-
pressor Eplin-a is thus a novel cytoskeletal target gene
regulated by the actin-MAL-SRF pathway. We note that
high Eplin expression has been associated with stabilising
less dynamic actin structures and enhanced adhesion,
whereas SRF knockout and MRTF knockdown was shown
to have the opposite effects [23,24]. Conversely, MAL
overexpression results in enhanced cell spreading and
antiproliferative effects [19]. Although MRTFs are
required for experimental invasion and metastasis,
the MAL homolog myocardin was recently described as
a tumor suppressor [23,25]. Our study grants further
Figure 3 Eplin-a expression is controlled by mutant actins and
MAL/MRTF transcriptional coactivators. (A) Cotransfection of NIH
3T3 cells with the indicated Eplin-a reporter and actin wildtype (wt),
non-polymerisable mutant actin R62D, and F-actin stabilising mutant
actin G15S [16,17]. Following cytochalasin treatment, the relative
Luciferase activity was determined as before. (B) Transient expression
of constitutively active MAL ΔN or MAL affect the Eplin-a mRNA level.
Cells were transiently infected with the indicated pLPCX-derived
retrovirus [19]. Two days later, the total mRNA was isolated and
analysed for Eplin-a mRNA by quantitative RT-PCR as before. (C) Effect
of dominant negative MAL ΔNΔB, MAL ΔNΔC, or double knockdown of
MRTFs, on serum-stimulated Eplin-a expression. Infection was done
with derivatives of either pLPCX or pSUPER-Retro (pSR, control),
generating a shRNA targeting both MAL/MRTF-A and MRTF-B [19].
Two days after infection, cells were stimulated with serum if indicated
(FCS, 15%, 90 min), and the relative Eplin-a mRNA induction was
quantified. (D) Effect of constitutively active MAL ΔNa n dM A L ,o r
double knockdown of MRTFs, on Eplin-a expression in EpRas epithelial
cells. Shown is the average mRNA amount of EpRas cells stably
infected with the indicated MAL constructs, compared to the mock-
infected control cells (pLPCX and pSR control, respectively). Error bars,
SEM (n = 3). Asterisk, significant activation; double asterisk, significant
repression (p < 0.01, unpaired student’st - t e s t ) .
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Page 4 of 6Figure 4 Recruitment of MAL and SRF to the Eplin-a promoter. Chromatin immunoprecipitation was performed using starved (un.)
and stimulated NIH 3T3 cells (CD,2μM; FCS, 15%; 30 min), as indicated. Following chromatin preparation, antibodies specific for SRF (G-20,
Santa Cruz) and MAL (homemade rabbit serum #79), or a negative control antibody (ctrl), were used for IP as described [19]. The primers
used for amplifying an Eplin-a promoter fragment around the putative CarG box were: ® (
-178AAAAAGTCTCTCCCTTCCAATGT),
¬ (
-15GTTACTGCCCTGCCACAAG). (A) Cytochalasin treatment induces recruitment of MAL to the Eplin-a and srf gene. Immunoprecipitated
and input Eplin-a, srf and gapdh promoter fragments were amplified by conventional PCR and visualised by agarose gel electrophoresis.
(B) Real-time PCR was performed from three independent chromatin preparations and IPs. Shown is the relative quantitation of gapdh, srf and
Eplin-a promoter fragments in SRF and MAL immunoprecipitates, expressed in % of the input chromatin. Error bars, SEM (n = 3). (C) Quantitation
of MAL and SRF recruitment to the Eplin-a, srf and gapdh gene following serum stimulation. Bound Eplin-a in MAL immunoprecipitates was
increased 5.8 fold by FCS.
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MAL/MRTF family members and tumor suppressors such
as Eplin-a during cancer progression.
Additional file 1: Actin mutants affect serum induction of Eplin-a.
(A) Cotransfection of NIH 3T3 cells with the indicated Eplin-a reporter
and actin wildtype (wt), non-polymerisable mutant actin R62D, and F-
actin stabilising mutant actin G15S [1617]. One day later, cells were
serum-starved (un., 0.5% FCS, 20 h) and stimulated (FCS, 15%, 7 h) if
indicated, and the relative luciferase activity was determined as before.
(B) Following transient transfection with the constructs indicated, cells
were serum-starved for 40 h prior to serum-stimulation for 90 min as
indicated. The total mRNA was isolated and analysed for Eplin-a mRNA
by quantitative RT-PCR.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-60-
S1.PDF]
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